Hot Investor Mandate: Silicon Valley VC Invests in Therapeutics, Diagnostics, Tools and Devices

5 Dec

A venture capital firm with investment teams in Silicon Valley (headquarters) and Europe is currently investing out of their third $355M fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. the firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Equity Firm Invests Globally in Surgical Innovations

5 Dec

A private equity firm founded in 2014 and is based in New York and Montreal. The firm manages the a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals, with a focus on surgery. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Pharma Looks for Early Stage Partnerships in CNS, Immunology, Liver Disease and More

5 Dec

A pharmaceutical company based in Asia is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Europe Fund Invests Early in Therapeutics, Diagnostics and Agtech

5 Dec

A venture capital firm based in the Benelux region is focused on identifying and investing in promising European companies. The firm generally invests from the very early stages from Seed to Series A and often acts as the first institutional investor, but also reserves 1/3 of the fund to more late-stage opportunities as well. The firm could invest as little as $200K or up to $3M in a first investment round, depending on the company’s current stage of development. The firm seeks to invest in companies that have a presence in Europe.

The firm invests broadly across therapeutics, diagnostics, and agriculture, but does not invest in medical devices, healthcare IT, or bioinformatics. The is open to all different types of technologies and indications.

The firm can act as either a lead or co-investor. In cases where the firm acts as the first institutional investor, the firm will seek board representation and take an active role in helping the company grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Life Science Nation’s, Focus on Cures Accelerator (FOC), Now Offering a Fundraising Campaign Curriculum

27 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN recently launched the Focus on Cures (FOC) Accelerator that helps high-growth, international startup companies move into the global partnering arena through a two-week Boston-based immersion program, titled MKT 466: Funding and Partnering Immersion Course, integrated into LSN’s global partnering network and the RESI conference series. The theme of the FOC accelerator is to create a funnel of elite, top domestic and foreign startups that need to raise angel, seed, series A and B rounds. This course solves an early stage funding challenge: there is no standardized methodology for teaching a company how to brand and message itself and efficiently manage a fundraising campaign. There is no reliable, accurate, and current partner and investor database (besides LSN’s) to get a company a list of global partners that are a fit for their stage of development and product set. Very few entrepreneurs are actually taught how to launch and manage a fundraising campaign, never mind training CEOs how to make an introductory phone call or write an introductory email. Most importantly, no one teaches the holy grail of canvassing for capital, which is, how to follow up.

– Incubator
– Accelerator
– Government Agency
– Private Firm Seeking Funding

Participants in the course receive:

  • A year subscription to the LSN investor database, valued at $6,995
  • Branding and messaging collateral for fund raising campaign, (including a logo, tagline, one page data sheet, two page executive summary, and 10-12 slide pitch), valued at $15K
  • A ticket to the next RESI conference to launch the fundraising campaign, valued at $3,000

The course is $10,000 per company, for services valued at $25,000, held at the LSN corporate headquarters in Downtown Crossing, Boston. Each company is expected to send one business and one science executive for the two week immersion class. The first class will be held from May 25th through Jun 5th, leading up to RESI San Diego, taking place on Monday, June 8th.

FOC Accelerator – MKT 466 Funding and Partnering Immersion Course

MKT466 is a unique two-week immersion course designed for life science entrepreneurs to experience the best methodologies for reaching out and establishing a dialogue with partners and  investors, building a relationship and, ultimately, securing capital allocations.

The morning sessions are 3-hour classes teaching the fundamental business development and marketing skills needed to formulate a company theme, create a corporate brand with appropriate messaging and market your firm to investors and strategic partners within the life science arena. (See details in the morning class outline)

The afternoon sessions include 1 hour of meeting the players in the Massachusetts life science ecosystem and 2 hours of curating and reaching out to a list of global investors and channel partners:

  1. Utilize LSN’s Company Database to build a full picture of global landscape of competitors
  2. Utilize LSN’s Investor Database to find investors and partners that are a fit for your stage of development and product set and aggregate a global target list
  3. Refine investor-centric marketing collateral (following the instructions of the Branding and Messaging class)
  4. Leverage your infrastructure to do email marketing campaigns and nurture leads in a CRM
  5. Start email and phone canvassing each day, supervised and mentored by LSN expert BD staff
  6. Set up intro phone calls and meetings
  7. Prepare for the upcoming RESI conference

NEW! RESI Launches Featured Company Pitch Session

27 Nov

By Karen Deyo, Senior Investor Research Analyst, LSN

Are you looking to raise a private financing round or find a strategic partner for your life science startup?  The 27th Redefining Early Stage Investments (RESI) Partnering Conference is offering an opportunity to present your firm at our San Francisco event taking place on January 14th, 2020 event taking place at the Marines’ Memorial Club and Hotel near Union Square. We expect 500+ early stage investors to attend RESI San Francisco 2020, making this a unique opportunity to get your company’s message out.

Featured Pitch Sessions

Early Stage firms seeking licensing deals or Seed, Angel, Series A or B funding can secure a 15-minute presentation slot at the upcoming RESI Partnering Conference.  With RESI’s focused audience of life science investors, and a 1:1 ratio of investors to startups, presenting at RESI is a unique opportunity to get in front of early stage partners. RESI will host over 500 global early stage investors ranging from family offices and angels to strategic Pharma and MedTech players. Presenting at RESI gives companies an opportunity to build their profile.

If your firm is interested in presenting in the Early Stage Company Pitch Sessions please click below.  You will be required to submit a two-page executive summary and 10-12 page pitch deck with your application.

Deadline for applications December 12th 2019.

Fee structure

  • RESI registration fee per attendee (register here)
  • Presentation fee per company:  $1,500 

Who should present?

Any life science company that is developing products in the Drugs, Devices, Diagnostics or Digital Health arena and is seeking licensing or investment.

Presentation Details:

  • Early Stage companies are invited to request a 15-minute company presentation.
  • Presenting companies will be featured in the LSN Newsletter, RESI website and in the RESI conference program guide.

What about the RESI Innovation Challenge?

Those who are familiar with RESI know of the RESI Innovation Challenge, a competition for companies on the day of the conference, where they present posters in the exhibit hall and compete for ‘investments’ of ‘RESI Cash’ from attendees, with the most successful winning prizes at the end of the day. The RESI Innovation Challenge is unique in that it involves a rigorous merit-based selection process that assesses the ‘investability’ of a company based on the innovativeness of their technology, the stage of development and potential market size, to name a few of the many criteria. The Innovation Challenge has always been extremely selective, with many more applying than are accepted to participate. Participation in the Innovation Challenge for selected companies is at no extra cost, to ensure that the selective nature of the Innovation Challenge remains solely merit based (apply here). However, we have found that a large number of companies would like the opportunity to present their companies to the broad audience in attendance at RESI. To accommodate them, we are launching the RESI Featured Company Pitch Sessions.

RESI BACK TO EUROPE IN 2020! Save the Date!

27 Nov

By Gregory Mannix, Vice President International Business Development, LSN

RESI is returning to the Old Continent for the 2nd RESI Europe conference, this time to be held at the Hyatt Regency Etoile in Paris on March 23rd, 2020. Mark your calendar because you will not want to miss this unique gathering of 200+ global early stage life science investors.

← Older Entries
Newer Entries →